Citi lowered the firm’s price target on Bruker (BRKR) to $50 from $75 and keeps a Buy rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker’s Strong Market Position and Growth Potential Drive Buy Rating
- Bruker Corporation: A Strategic Buy Amid Market Concerns and Growth Opportunities
- Bruker’s Promising Market Position and Growth Prospects Justify Buy Rating
- Bruker Maintains Strong Buy Rating Amidst Innovations in Spatial Biology and Strategic Financial Management
- Bruker Expands Board with Appointment of Laura Francis